You're both right on the money wyatt and mark - the unique things about BIEL and its cornerstone product ActiPatch are that it's a paradigm shift in the use of PEMF therapy to treat pain on a massive global scale, previously dealt with by chemical drugs. 3 or 4 years ago, FDA openly said id didn't have the experts to assess tis and went and hired them. and here we are, FINAL ORDER, CLASS II, FDA, USA!
ActiPatch is not a heat, tingle, massage or feel good pad; it's an approved scientific pain and inflammation process that moderates pain, deals with edema and stimulates healing. BIEL has a patented, till 2030 so far, miniaturized device that people can buy OTC, take home and deal with pain effectively, no pills, no doc, no waiting, no side-effects, better life.
2 problems. BIEL was not a big pharma using billions in drug profits to finance its next drug, while trading on the NYSE. Also, being a tiny company with no money, trading on the Pinks and diluting shares, which its CEO fully disclosed, when it had to, but not to the extent people assume, in order to finance this breakthrough, has made BIEL a trash hound, beaten by most who see it. But not anymore.
FDA Final Order, October 13, and don't think for one second big pharma didn't just wake up and gulp big. Go into any drugstore on earth, look at the OTC pain section, look at the pharmacist's pain inventory stacked on his shelves, go find "Tylenol global sales" including the Rx, then top 10 Tylenol competitors. Now start cutting because there are over 100 Million sufferers of mild, medium and severe chronic pain just here in the US. Now think global again and about any chronic pain you or family members have had, your grandfathers your parents, your mother-in-law (imagine her without pain) Johnny's chronic back and shoulder-fixed, pain-free! Now think of a logical exchange for BIEL shares to trade on. Now think tsunami. Yamayama
AI
Market Data 
Markets 
